Japan stocks jump 2% on hopes of coronavirus treatment; China’s manufacturing data misses expectations

Gilead Sciences said preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five-day dosage of remdesivir improved and more than half were discharged from the …
( read original story …)

---